Designing Longevity
Skip to main content
Compounded GLP-1

Mochi Health

Flat-rate with a vertically-integrated pharmacy under active state and federal scrutiny

Reviewed by Designing Longevity Editorial · last fact-checked May 1, 2026

2.8

out of 5

No financial relationship with Mochi Health. Editorial inclusion only.

Visit Mochi Health

Verdict in one glance

Best for

  • Users specifically seeking flat-rate dose-independent pricing AND comfortable with the pharmacy enforcement record

    The flat-rate $99/mo and $199/mo model genuinely beats the cohort on titration economics for users who land at higher therapeutic doses. This only makes sense if you have read the WA State enforcement record on Aequita and decided you're comfortable with it.

Look elsewhere if

  • Anyone weighing pharmacy quality signals at all

    The Aequita situation (Notice of Immediate Jeopardy, unlicensed-worker compounding allegations substantiated by state enforcement and Agreed Order signed without contest) is a category of negative signal that is materially different from anything else in our - cohort. For users who weight pharmacy quality at all, choose TrimRx (-accredited B, partner pharmacies, no comparable enforcement) or Eden (vertically integrated without comparable enforcement) instead.

  • Users sensitive to ongoing manufacturer litigation

    Two active federal lawsuits is one more than any other - provider in our cohort. The Novo case adds a corporate-practice-of-medicine claim that is structurally different from marketing-only litigation.

Our take

Mochi Health is the most complicated provider in our cohort to score. The consumer-experience signal is strong ( 4.4/5 across 15,600+ reviews with no fraud notice, board-certified obesity-medicine physicians, genuinely innovative flat-rate dose-independent pricing) and the FDA record is clean. The counterweight is heavy and substantively different from anything else in our cohort: Washington State pharmacy enforcement against Mochi's affiliated compounding pharmacy Aequita escalated to a Notice of Immediate Jeopardy after whistleblower allegations of unlicensed-worker sterile compounding and improper cold-chain shipping (frozen children's popsicles instead of medical-grade ice packs). Two active manufacturer lawsuits compound the picture. We list Mochi because the pricing model is genuinely interesting and the consumer experience is broadly positive, but we cannot recommend Mochi as a default option for any cohort segment given the substantiated pharmacy-quality concerns. Choose Mochi only if the flat-rate dose-independent pricing is specifically what you want and you have read the WA State enforcement record and decided you are comfortable with it.

Pros

  • 4.4/5 across 15,600+ reviews with no fraud notice (largest sample in our - cohort)
  • Genuinely innovative flat-rate pricing: $99/mo and $199/mo at every dose tier including max therapeutic dose
  • Board-certified obesity-medicine physicians on the prescribing side
  • Vertically integrated through Aequita Pharmacy (in theory cleaner sourcing chain)
  • No on Mochi or Aequita verified at capture date

Cons

  • Washington State Limited Stop Service + Notice of Immediate Jeopardy on Aequita Pharmacy after substantiated whistleblower allegations of unlicensed-worker sterile compounding
  • Cold-chain shipping documented with frozen children's popsicles ("Otter Pops") instead of medical-grade ice packs
  • TWO active manufacturer lawsuits in N.D. Cal.: Eli Lilly (April 2025) and Novo Nordisk 5:25-cv-06563 (August 2025)
  • Novo lawsuit specifically alleges unlicensed corporate practice of medicine, broader than typical marketing-claim litigation
  • NOT Accredited; complaints cluster on cancellation and refund issues
  • Vertical-integration marketing story directly contradicted by substantiated pharmacy-operational allegations

Pricing

$79/mo membership ($69 with insurance) + $99/mo semaglutide or $199/mo tirzepatide flat

Turnaround

Same-week Rx after async intake and (where required) bloodwork

States served

All 50

Last verified

May 1, 2026

What Mochi Health says, and what we found

The provider's own marketing claims, paired with our verdict. Color-coded so you can scan: green for verified, amber for stated-but-unconfirmed, violet for context.

VerifiedPricing

Confirmed against the public FAQ. Flat-rate dose-independence is genuinely uncommon in the cohort and a real product differentiator.

Mochi Health offers at $99/month and compounded at $199/month at every dose tier, with no price escalation as patients titrate up.

Mochi Health FAQ · captured May 1, 2026 · source

VerifiedSourcing

Confirmed. Aequita is the entity under direct WA State pharmacy enforcement; its ownership and operating structure was the subject of the February 2026 KING 5 News investigation.

Mochi prescriptions are filled through Aequita, a Mochi-affiliated compounding pharmacy.

Mochi Health public materials · captured May 1, 2026 · source

VerifiedCare model

Confirmed. Forum and review commentary repeatedly cites individual Mochi physicians by name with their credentials. The clinical-side care model is a real cohort differentiator.

Mochi provides board-certified obesity medicine physicians for prescribing.

Mochi Health public materials · captured May 1, 2026 · source

Rubric breakdown

How this is scored

Licensure

20% weight
2.0/5

Active state license, no recent disciplinary actions, no FDA enforcement.

No on Mochi Health Corp. or Aequita Pharmacy verified at capture date. Counterweights are heavy: a Washington State Department of Health Limited Stop Service that escalated to a Notice of Immediate Jeopardy against Aequita Pharmacy (the compounding pharmacy that fills Mochi prescriptions), plus two active federal manufacturer lawsuits in N.D. Cal. (Eli Lilly v. Mochi Health, April 2025; Novo Nordisk A/S et al v. Mochi Health Corp., 5:25-cv-06563, August 2025). The Novo lawsuit specifically alleges unlicensed corporate practice of medicine in addition to false advertising.

What we verified (6)

  • No FDA warning letter on Mochi Health or Aequita

    Federal database

    Checked May 1, 2026 · source

  • Mochi Health Corp. operating entity

    Business filing

    San Francisco, CA. profile registered as health care category. Medical Board of California license number 554576 listed on the BBB profile.

    Checked May 1, 2026 · source

  • WA State Limited Stop Service + Notice of Immediate Jeopardy on Aequita Pharmacy

    State pharmacy enforcement

    Washington State Department of Health Pharmacy Quality Assurance Commission issued a Limited Stop Service against Aequita Pharmacy (Mochi's affiliated compounding pharmacy in Kirkland, WA) that ultimately escalated to a Notice of Immediate Jeopardy. State enforcement substantiated whistleblower allegations that unlicensed day laborers handled sterile-compounding operations and that medications shipped using frozen children's popsicles instead of medical-grade ice packs for cold-chain. Aequita's listed owner signed an Agreed Order in July 2025 that did not contest the findings. This is a product-quality regulatory action against the pharmacy that fills Mochi prescriptions, materially different from marketing-claim litigation.

    Checked May 1, 2026 · source

  • KING 5 News investigation on Aequita

    Press investigation

    KING 5 News (Seattle ABC affiliate) investigative report dated February 20, 2026 broke the whistleblower story with on-camera evidence including the Otter Pops cold-chain shipping. Independent press coverage substantiates the regulatory record.

    Checked May 1, 2026 · source

  • Eli Lilly v. Mochi Health (compounded tirzepatide marketing)

    Civil litigation

    Filed April 2025 in N.D. Cal. alongside parallel cases against Henry Meds, Fella Health, and Willow Health. Lanham Act and California consumer-protection claims over allegedly deceptive marketing of as personalized and equivalent to /.

    Checked May 1, 2026 · source

  • Novo Nordisk A/S et al v. Mochi Health Corp. (5:25-cv-06563)

    Civil litigation

    Filed August 4, 2025 in N.D. Cal. as part of Novo's broader 14-defendant - enforcement effort. The complaint adds an unlicensed-corporate-practice-of-medicine claim under California law, materially broader than the Eli Lilly case which is marketing-only.

    Checked May 1, 2026 · source

Accreditation

20% weight
2.5/5

PCAB, LegitScript, NABP, USP <797> stack.

Mochi Health is NOT Accredited. Profile came to BBB attention in December 2023 with complaints concerning cancellation and refunds. certification is claimed by the company on its public materials but not independently confirmable on a public registry (LegitScript does not publish a per-merchant directory). Affiliated pharmacy Aequita's WA State enforcement is the dominant accreditation-level signal, materially weaker than any cohort competitor.

What we verified (3)

  • BBB profile, NOT Accredited

    Accreditation

    Health-care category in San Francisco, CA. Came to attention December 2023, complaint review completed April 2026. Complaints concentrate on cancellation and refund issues.

    Checked May 1, 2026 · source

  • LegitScript Healthcare Merchant Certification

    Accreditation

    Mochi materials claim certification. Not independently confirmable on a public registry; advertising on Google and Meta generally requires LegitScript, so the inference is reasonable, but we cannot point to a public source.

    Checked May 1, 2026 · source

  • Affiliated pharmacy WA State enforcement

    Pharmacy regulatory

    The compounding pharmacy that fills Mochi prescriptions (Aequita) is the entity under direct state pharmacy regulatory action. or NABP accreditations on Aequita are not surfaced publicly, and the WA State action specifically cited deficient sterile-compounding practices.

    Checked May 1, 2026

Transparency

20% weight
3.0/5

CoAs, ingredient sourcing, formulation disclosure.

Mochi publishes its flat-rate pricing model clearly ($99/mo and $199/mo regardless of dose), and the membership tiers are documented. Counterweight: the gap between Mochi's marketing of vertically-integrated pharmacy quality and the substantiated whistleblower allegations about Aequita's actual operations is itself a transparency failure. The company's vertical-integration story was used as a quality differentiator in marketing while the affiliated pharmacy was operating with the issues that drove the WA enforcement.

What we verified (3)

  • Flat-rate pricing model published

    Pricing transparency

    $99/mo at every dose tier including max therapeutic dose; compounded $199/mo flat. Membership $79/mo or $69/mo with insurance plan participation. 50% off first month ($39).

    Checked May 1, 2026 · source

  • Vertical-integration story vs operational reality

    Care-model transparency

    Mochi marketed pharmacy quality control through Aequita ownership. WA State enforcement substantiated that Aequita was using unlicensed workers and improper cold-chain shipping, which contradicts the marketing. We treat this as a transparency failure even if the marketing language was technically true at higher levels of abstraction.

    Checked May 1, 2026 · source

  • Compounded vs FDA-approved disclaimer published

    Compliance disclosure

    Checked May 1, 2026

Product quality

15% weight
2.0/5

Independent test results, recall history, supply-chain controls.

The medication that ships to Mochi patients is filled through Aequita Pharmacy. Aequita is the entity that received the WA State Limited Stop Service plus Notice of Immediate Jeopardy after substantiated allegations of unlicensed-worker compounding and improper cold-chain shipping (frozen children's popsicles in lieu of medical-grade ice packs for biologics that require temperature stability). Cold chain matters meaningfully for compounded medications because and are biologics whose potency degrades with temperature excursions. We treat this as the most material product-quality flag in our entire marketplace cohort.

What we verified (4)

  • No FDA recalls on Mochi-distributed product

    Recall history

    No formal FDA recalls. The WA State action is at the state-pharmacy level, distinct from FDA recall infrastructure.

    Checked May 1, 2026 · source

  • Aequita unlicensed-worker compounding allegations substantiated

    Pharmacy operations

    Per WA State investigation: Aequita's manager hired day laborers from Home Depot and Lowes parking lots starting July 2025 to perform sterile-compounding tasks, with deficient training and supervision. The Agreed Order signed by Aequita's listed owner Nathan Kenney in July 2025 did not contest these findings.

    Checked May 1, 2026 · source

  • Cold-chain shipping with consumer-grade ice (Otter Pops)

    Pharmacy operations

    KING 5 News investigation documented Aequita employees wrapping medication vials in Otter Pops (frozen children's popsicles) instead of medical-grade ice packs for cold-chain shipping. and are temperature-sensitive biologics; cold-chain failures can degrade potency.

    Checked May 1, 2026 · source

  • Board-certified obesity medicine physicians on prescribing side

    Care model

    Mochi's prescribing-side care model uses board-certified obesity medicine physicians, which is a real differentiator on the clinical side. The pharmacy-side issues are operationally separate but cumulative for the patient experience.

    Checked May 1, 2026

Pricing

15% weight
4.0/5

Value within the category, no surprise fees, refund policy.

Genuinely innovative flat-rate pricing model. $99/month for and $199/month for compounded at every dose tier, including the maximum therapeutic dose. Membership $79/mo standalone or $69/mo with insurance Wellness Plus tier. All-in roughly $178/mo for semaglutide or $278/mo for tirzepatide. The flat-rate dose-independence is a real differentiator; most cohort competitors raise prices as patients titrate up to higher doses. The honest counterweight: pricing is the primary axis Mochi competes on, and pricing alone is not enough to outweigh the pharmacy-quality concerns.

What we verified (2)

  • Flat-rate pricing across all doses

    Pricing transparency

    $99/mo and $199/mo at every dose tier including max therapeutic dose. Most cohort competitors charge more at higher doses; Mochi explicitly does not.

    Checked May 1, 2026 · source

  • No insurance accepted on compounded line

    Coverage

    Cash-pay only on , consistent with the rest of the category. Brand-name GLP-1 paths billed through insurance separately. HSA/FSA accepted.

    Checked May 1, 2026

Customer service

10% weight
4.0/5

Refund policy, support quality, complaint history.

4.4/5 across roughly 15,600+ reviews, the largest external review sample of any - provider in our cohort. No suspected-fraudulent-review notice on the page at capture date. The disconnect between the strong consumer-experience signal and the substantiated pharmacy-quality issues at Aequita is itself the story: most patients have not encountered the operational issues that drove the WA State enforcement, but the issues are documented and material.

What we verified (2)

  • Trustpilot 4.4/5 across roughly 15,600+ reviews

    External review

    Largest external review sample in our - cohort. No suspected-fraudulent-review notice on the page at capture date. Sentiment skews positive on the consumer-experience side (clinician quality, ease of process).

    Checked May 1, 2026 · source

  • BBB complaint pattern on cancellation and refunds

    Complaint history

    Profile came to attention December 2023; complaints concentrate on cancellation and refund issues. Mochi has been responsive to most BBB complaints per public records.

    Checked May 1, 2026 · source

Public reviews

What we found across third-party review platforms. These are external sentiment signals, not our scoring inputs.

Trustpilot

4.4/5 across roughly 15,600+ reviews. The largest external review sample in our - cohort. No suspected-fraudulent-review notice. Positives concentrate on physician quality (named clinicians cited frequently) and the ease of the flat-rate program. Negatives concentrate on cancellation and refund friction.

Captured May 1, 2026Source

Better Business Bureau

NOT Accredited. Health-care category in San Francisco. Came to attention December 2023; complaint review completed April 2026. Complaints concentrate on cancellation and refund issues. Mochi has been responsive to most BBB complaints per public records.

Captured May 1, 2026Source

KING 5 News investigation

KING 5 News (Seattle ABC affiliate) investigation dated February 20, 2026 documented whistleblower allegations of unlicensed Home Depot and Lowes day laborers performing sterile compounding at Mochi's affiliated Aequita Pharmacy in Kirkland, WA, plus cold-chain shipping using frozen children's popsicles instead of medical-grade ice packs. Substantiated by subsequent WA State enforcement.

Captured May 1, 2026Source

Regulatory & legal history

FDA enforcement actions, manufacturer lawsuits, recalls, and other notable events on the public record.

  1. Lawsuit FiledApril 23, 2025

    Eli Lilly and Company filed Eli Lilly v. Mochi Health in the U.S. District Court for the Northern District of California, parallel to the cases against Henry Meds, Fella Health, and Willow Health. Lanham Act and California consumer-protection claims over allegedly deceptive marketing of as personalized and equivalent to and .

    Source
  2. State Board ActionJuly 1, 2025

    Aequita Pharmacy's listed owner pharmacist Nathan Kenney signed an Agreed Order with the Washington State Department of Health Pharmacy Quality Assurance Commission that did not contest findings of deficient sterile-compounding practices, including unlicensed staff performing sterile compounding without proper supervision.

    Source
  3. Lawsuit FiledAugust 4, 2025

    Novo Nordisk A/S et al v. Mochi Health Corp. et al, Case 5:25-cv-06563 filed in U.S. District Court for the Northern District of California as part of Novo Nordisk's broader 14-defendant - enforcement effort. The complaint adds an unlicensed-corporate-practice-of-medicine claim under California law alongside Lanham Act and false-advertising claims.

    Source
  4. Press CoverageFebruary 20, 2026

    KING 5 News (Seattle ABC affiliate) investigative report aired with on-camera evidence of whistleblower allegations against Aequita Pharmacy: unlicensed Home Depot and Lowes day laborers performing sterile compounding starting July 2025; cold-chain shipping using frozen children's Otter Pops popsicles instead of medical-grade ice packs.

    Source
  5. State Board ActionFebruary 23, 2026

    Washington State Department of Health Pharmacy Quality Assurance Commission issued a Limited Stop Service against Aequita Pharmacy that ultimately escalated to a Notice of Immediate Jeopardy. Aequita could not compound, dispense, deliver, or distribute products in Washington state until the action was resolved. Cited deficient sterile-compounding practices including untrained staff, inadequate supervision, and failure to adhere to sterile-compounding procedures designed to ensure product integrity and patient safety.

    Source

What to expect

  1. 1

    Async intake form

    10-15 min

    Online intake covering current weight, BMI, medical history, and weight-loss goals. Mochi advertises 50% off the first month ($39).

  2. 2

    Clinician review

    Same week

    Board-certified obesity-medicine physician reviews the intake and issues a prescription if appropriate. Same-week turnaround typical.

  3. 3

    Pharmacy fulfillment via Aequita

    3-7 days

    Approved routes to Aequita Pharmacy (Mochi-affiliated, Kirkland WA). Cold-chain shipping was documented as using frozen children's Otter Pops popsicles in 2025-2026 per KING 5 News investigation; the WA State enforcement action ordered corrective measures. Status of corrected shipping practices is worth confirming with Mochi directly before relying on cold-chain integrity for biologic medications.

  4. 4

    Ongoing membership

    Ongoing

    Membership $79/mo or $69/mo with insurance plan participation. complaints concentrate on cancellation and refund issues; cancel through documented in-app flow before next billing cycle if you are stopping.

Accreditations

State pharmacy/clinic license

Verified · May 1, 2026

LegitScript Certified

Unverified · May 1, 2026 · source

Frequently asked

What happened with Aequita Pharmacy?

Aequita is the compounding pharmacy that fills Mochi prescriptions, owned by Mochi Health. In February 2026, KING 5 News (Seattle ABC affiliate) broke an investigative story documenting whistleblower allegations that Aequita was using unlicensed day laborers from Home Depot and Lowes parking lots to perform sterile-compounding tasks, and that medication shipments used frozen children's Otter Pops popsicles instead of medical-grade ice packs for cold-chain. The Washington State Department of Health Pharmacy Quality Assurance Commission issued a Limited Stop Service against Aequita that ultimately escalated to a Notice of Immediate Jeopardy, the strongest pharmacy enforcement category. Aequita's listed owner Nathan Kenney signed an Agreed Order in July 2025 that did not contest the findings. This is the most material product-quality flag in our entire marketplace cohort.

Is Mochi Health legit?

Yes in the narrow sense: Mochi Health Corp. is a real company, no has been issued against Mochi or Aequita, prescriptions come from board-certified obesity medicine physicians, and shows 4.4/5 across 15,600+ reviews with no fraud notice. Whether 'legit' means trustworthy enough for you is a different question. The Washington State enforcement against the affiliated compounding pharmacy plus two active federal manufacturer lawsuits stack against Mochi in a way that is materially different from cohort competitors. We list Mochi because the pricing model is genuinely innovative, but we cannot recommend it as a default option for any cohort segment.

What about the Eli Lilly and Novo Nordisk lawsuits?

Two active federal lawsuits in the U.S. District Court for the Northern District of California. Eli Lilly v. Mochi Health was filed in April 2025 over marketing (parallel to the Henry Meds, Fella Health, and Willow Health cases). Novo Nordisk A/S et al v. Mochi Health Corp., Case 5:25-cv-06563 was filed August 4, 2025 as part of Novo's broader 14-defendant enforcement; the Novo complaint specifically adds an unlicensed-corporate-practice-of-medicine claim under California law alongside the Lanham Act false-advertising claims. The Novo claim is structurally different from typical marketing-only litigation; if it succeeds, it would constrain how Mochi can structure its prescribing relationships going forward.

Is the flat-rate pricing actually different from competitors?

Yes, in a genuinely useful way for users who titrate up to higher doses. Mochi's $99/month and $199/month compounded stay at the same price across every dose tier including the maximum therapeutic dose. Most cohort competitors charge more at higher doses, so users on max-dose protocols pay materially more elsewhere. If your protocol stays at lower doses, the pricing advantage is smaller. The pricing innovation is real; the question is whether it offsets the pharmacy-quality concerns.

How does Mochi compare to Henry Meds?

Different failure modes. Henry Meds has the cohort's worst rating (F with 25 unanswered complaints) and a suspected-fraudulent-review notice on its profile. Mochi has a clean Trustpilot signal (4.4/5 across 15K+ reviews, no fraud notice) but a worse pharmacy-quality flag because the affiliated compounding pharmacy received WA State enforcement up to and including a Notice of Immediate Jeopardy. Both have active Eli Lilly lawsuits; Mochi additionally has the Novo Nordisk corporate-practice-of-medicine case. For most readers, neither is the right default; choose TrimRx, Eden, or Ro instead unless a Mochi-specific differentiator (flat-rate pricing) or Henry Meds-specific differentiator (oral tablets) is the binding need.

Should I use Mochi if I have an existing prescription with them?

If you are an existing Mochi patient and the medication has been working for you with no apparent issues, this is a conversation to have with your prescribing clinician rather than a blanket recommendation from us. The cold-chain shipping documented in the KING 5 News investigation could affect medication potency in some shipments and not others; users who have not noticed efficacy issues may not have received affected product. Worth asking Mochi directly what cold-chain corrective measures they implemented post-WA State enforcement and whether they have changed compounding-pharmacy partners (the company has indicated they are working with multiple pharmacy partners; specifics worth confirming).

Update history

Every meaningful change to this profile, with a date stamp. We don't silently re-score.

  1. May 1, 2026

    Initial published profile. Sources HEAD-checked at publish time. Score (2.8) reflects the unusually-large gap between strong consumer-experience signals ( 4.4/5 across 15,600+ reviews; flat-rate pricing innovation; board-certified obesity-medicine physicians) and material pharmacy-quality and litigation counterweights (WA State Notice of Immediate Jeopardy on affiliated Aequita Pharmacy; two active manufacturer lawsuits including Novo Nordisk's corporate-practice-of-medicine claim). Honest framing: list because the pricing model is genuinely interesting and the consumer experience is positive, but cannot recommend as a default option for any cohort segment given the substantiated pharmacy-quality concerns.

Compare Mochi Health head-to-head

Stuck choosing? We pick a winner per use case in the comparisons below.

vs Eden

Independent head-to-head: Mochi Health vs Eden. Both own their compounding pharmacies, but only Mochi's drew a Washington State action.

See verdict

vs Henry Meds

Independent head-to-head: Mochi Health vs Henry Meds. Both face manufacturer lawsuits: pharmacy enforcement vs a BBB F rating and fraud notice.

See verdict

vs Ro

Independent head-to-head: Mochi Health vs Ro for GLP-1. Flat-rate compounded pricing and pharmacy enforcement vs the insured incumbent.

See verdict

vs TrimRx

Independent head-to-head: Mochi Health vs TrimRx for compounded GLP-1. Flat-rate pricing against Washington State pharmacy enforcement.

See verdict

Reviewed by Designing Longevity Editorial. Last fact-checked May 1, 2026.

Spot something out of date or wrong? Let us know and we'll re-check.

Back to all providers